← All trials
NCT00508261
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2007
- Primary completion
- May 1, 2008
- Completion date
- Oct 1, 2008
- First posted
- —
- Last posted
- —
- Enrollment
- 793
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- glyco-conjugate neisseria meningitidis serogroup c vaccine
- meningococcal (groups A, C, Y, W) diphtheria toxoid conjugate vaccine
- meningococcal (groups A, C, Y, W) diphtheria toxoid conjugate vaccine
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.